RNRohan Narayan

Rohan Narayan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rohan Narayan has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Inhibitors of Gut Bacterial l -Dopa Decarboxylation with Reduced Susceptibility to Host Metabolism

    by Rohan Narayan, Chi “Chip” Le, Jai K. Khurana, Vincent Nieto, Christine A. Olson, Peter J. Turnbaugh, Emily P. Balskus

    Microorganisms in the human gut influence the efficacy and metabolism of host-targeted small molecule therapeutics, including the frontline Parkinson’s disease drug levodopa (l-dopa). Previous work has identified a mechanism-based inhibitor of gut bacterial decarboxylases that degrade l-dopa, α-fluoromethyltyrosine (AFMT). However, early experiments with AFMT in rodent models suggested undesirable in vivo metabolism by host tyrosine hydroxylase, producing α-fluoromethyldopa, a metabolite likely to worsen Parkinson’s phenotypes and prevent application as an l-dopa cotreatment. Here, we demonstrate oxidation of AFMT to α-fluoromethyldopa in vitro by recombinant human tyrosine hydroxylase. We then develop AFMT analogues that retain activity against bacterial decarboxylases but have reduced susceptibility to host hydroxylation. Suitable arenes for inhibitor design were identified using assays with commercially available noncanonical amino acids, which revealed aryl difluorination as a promising modification. Difluoroaryl AFMT derivatives are less prone to degradation by tyrosine hydroxylase in vitro yet still inhibit l-dopa metabolism by bacterial decarboxylases. This work exemplifies how substrate reactivity can streamline design of mechanism-based enzyme inhibitors, as well as how constraints posed by the host can be incorporated during development of microbiome-targeted therapeutics. The compounds reported here are promising starting points for future studies in animal models and further exploration of gut bacterial effects on l-dopa treatment efficacy.

  • Open Access

    Inhibitors of gut bacterial L-dopa decarboxylation with reduced susceptibility to host metabolism

    by Rohan Narayan, Chi “Chip” Le, Jai K. Khurana, Vincent Nieto, Christine A. Olson, Peter J. Turnbaugh, Emily P. Balskus

    Microorganisms in the human gut influence the efficacy and metabolism of host-targeted small molecule therapeutics, including the frontline Parkinson’s disease drug levodopa (L-dopa). Previous work has identified a mechanism-based inhibitor of gut bacterial decarboxylases that degrade L-dopa, α-fluoromethyltyrosine (AFMT). However, early experiments with AFMT in rodent models suggested undesirable in vivo metabolism by host tyrosine hydroxylase, producing a metabolite likely to worsen Parkinson’s phenotypes and prevent application as an L-dopa co-treatment. Here, we demonstrate oxidation of AFMT in vitro by recombinant human tyrosine hydroxylase. We then develop AFMT analogs that retain activity against bacterial decarboxylases but have reduced susceptibility to host hydroxylation. Suitable arenes for inhibitor design were identified using assays with commercially available noncanonical amino acids, which revealed aryl difluorination as a promising modification. Difluoroaryl AFMT derivatives are less prone to degradation by tyrosine hydroxylase in vitro yet still inhibit L-dopa metabolism by bacterial decarboxylases. This work exemplifies how substrate reactivity can streamline design of mechanism-based enzyme inhibitors, as well as how constraints posed by the host can be incorporated during development of microbiome-targeted therapeutics. The compounds reported here are promising starting points for future studies in animal models and further exploration of gut bacterial effects on L-dopa treatment efficacy.


  • Open Access

    Small molecule splicing modulators that disrupt O-GlcNAc homeostasis

    by Steven S. Cheng, Alison C. Mody, Amedeo Vetere, Ashwin Govindan, Yewon Lee, Danielle E. Khost, Rohan Narayan, Timothy B. Sackton, Nicholas K. Conrad, Bridget K. Wagner, et al.

    O-Linked N-acetylglucosamine (O-GlcNAc) is a nucleocytoplasmic post-translational modification that is tightly regulated by O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). Dysregulation of O-GlcNAc in human disease has motivated efforts to therapeutically modulate O-GlcNAc. Drug repurposing efforts can accelerate these campaigns and unveil how clinically relevant compounds and pathways intersect with O-GlcNAc. Here we report the results of three parallel drug repurposing screens against the O-GlcNAc cycling enzymes in cells and in vitro that reveal kinase inhibitors GSK690693 and Y-33075 act as splicing modulators that disrupt O-GlcNAc homeostasis and simultaneously downregulate OGT and OGA. These effects are independent of their respective annotated targets, AKT and ROCK, and are distinct from OGT and OGA inhibitors and similar kinase inhibitors. Evaluation of a panel of splicing modulators revealed three additional potent compounds (OTS964, indisulam, GNF2133) that similarly downregulate OGT and OGA with distinct splicing profiles. These findings reveal previously unobserved splicing modulator chemotypes and approaches to disrupt O-GlcNAc homeostasis.


  • Open Access

    Publisher Correction: Targeting the human gut microbiome with small-molecule inhibitors

    by Amelia Y. M. Woo, Miguel A. Aguilar Ramos, Rohan Narayan, Khyle C. Richards-Corke, Michelle L. Wang, Walter J. Sandoval-Espinola, Emily P. Balskus

  • Targeting the human gut microbiome with small-molecule inhibitors

    by Amelia Y. M. Woo, Miguel A. Aguilar Ramos, Rohan Narayan, Khyle C. Richards-Corke, Michelle L. Wang, Walter J. Sandoval-Espinola, Emily P. Balskus

    The human gut microbiome is a complex microbial community that is strongly linked to both host health and disease. However, the detailed molecular mechanisms underlying the effects of these microorganisms on host biology remain largely uncharacterized. The development of non-lethal, small-molecule inhibitors that target specific gut microbial activities enables a powerful but underutilized approach to studying the gut microbiome and a promising therapeutic strategy. In this Review, we will discuss the challenges of studying this microbial community, the historic use of small-molecule inhibitors in microbial ecology, and recent applications of this strategy. We also discuss the evidence suggesting that host-targeted drugs can affect the growth and metabolism of gut microbes. Finally, we address the issues of developing and implementing microbiome-targeted small-molecule inhibitors and define important future directions for this research.